Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Tadashi Uwagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7194-8427; OpenAlex author ID A5014949040. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  2. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  3. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  4. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  5. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. First author DOI 10.1007/s00520-023-08206-3↗
  6. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  7. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  8. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  9. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  10. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… First author DOI 10.1007/s12032-021-01625-4↗
  11. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Co-author DOI 10.1093/carcin/bgac060↗
  12. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  13. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001767↗
  14. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  15. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. First author DOI 10.21873/anticanres.12485↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenei Furukawa · 13 shared papers, 2021–2026 · strength 2.26
  2. Toru Ikegami · 12 shared papers, 2021–2026 · strength 2.12
  3. Yoshihiro Shirai · 12 shared papers, 2021–2026 · strength 2.12
  4. Shinji Onda · 12 shared papers, 2018–2026 · strength 2.09
  5. Koichiro Haruki · 11 shared papers, 2018–2026 · strength 1.91
  6. Masashi Tsunematsu · 8 shared papers, 2022–2026 · strength 1.58
  7. Takeshi Gocho · 9 shared papers, 2018–2026 · strength 1.46
  8. Ryoga Hamura · 9 shared papers, 2021–2025 · strength 1.45
  9. Michinori Matsumoto · 6 shared papers, 2023–2026 · strength 1.23
  10. Mitsuru Yanagaki · 5 shared papers, 2021–2026 · strength 0.92
  11. Taro Sakamoto · 5 shared papers, 2018–2024 · strength 0.73
  12. Tomohiko Taniai · 4 shared papers, 2021–2025 · strength 0.63
  13. Kyohei Abe · 4 shared papers, 2018–2025 · strength 0.61
  14. Norimitsu Okui · 3 shared papers, 2023–2025 · strength 0.61
  15. Hiroaki Shiba · 3 shared papers, 2021–2022 · strength 0.41
  16. Yoshiaki Tanji · 2 shared papers, 2023–2025 · strength 0.38
  17. Katsuhiko K. Yanaga · 3 shared papers, 2018–2022 · strength 0.37
  18. Shuichi Fujioka · 2 shared papers, 2022–2023 · strength 0.29
  19. Hironori Shiozaki · 2 shared papers, 2021–2022 · strength 0.28
  20. Takashi Horiuchi · 2 shared papers, 2021–2022 · strength 0.25
  21. Yosuke Igarashi · 1 shared paper, 2025 · strength 0.22
  22. Shunta Ishizaki · 1 shared paper, 2023 · strength 0.18
  23. Tohru Utsunomiya · 1 shared paper, 2023 · strength 0.15
  24. Mototsugu Shimokawa · 1 shared paper, 2023 · strength 0.15
  25. Keishi Sugimachi · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.